ArticleFrontiers in endocrinology2026
Metformin attenuates diabetic osteoporosis via the miR-21 mediated Mef2c/Sost pathway.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: ObjectiveThis study aimed to explore the role of the Methods: We compared bone mineral density (BMD), bone turnover biomarkers, and bone miR-21 expression levels between elderly female patients with and without diabetes. Diabetic mice and high-glucose-treated MLO-Y4 osteocytes were used to explore the involvement of the Results: Diabetic patients exhibited decreased bone miR-21 expression and reduced BMD, both of which were positively correlated with glycemic control status. Consistently, miR-21 was significantly downregulated in diabetic mice and high-glucose-cultured MLO-Y4 osteocytes. Both miR-21 and diabetic mice presented elevated protein levels of MEF2C and sclerostin, reduced expression of Cyclin D1 and RUNX2, as well as impaired bone strength and bone quality. As a direct target gene of miR-21, Conclusion: The
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.